Brain-Delivered gene therapy tested to halt devastating Early-Onset dementia
Disease control
Recruiting now
This early-phase study is testing a one-time gene therapy called AVB-101 for people with a specific genetic form of frontotemporal dementia (FTD-GRN). The therapy is designed to be delivered directly into the brain to restore a missing protein and potentially slow or stop disease…
Phase: PHASE1, PHASE2 • Sponsor: AviadoBio Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC